Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DoceRamPem in Metastatic or Recurrent NSCLC
NCT04340882Phase 2Active, not recruiting
- Sponsor
- Emory University
- Start
- Jun 2020
- Primary completion
- Apr 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by Emory University. Primary endpoint: Progression-Free Survival rate at 6 months. Started Jun 2020; status: active, not recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04340882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04340882.